Yi Sun, Saerom Kim, SeungYoun Shin, Kathryn Takemura, Gabriel S Matos, Cristina Lazzarini, Krupanandan Haranahalli, Julia Zambito, Ashna Garg, Maurizio Del Poeta, Iwao Ojima
Clinically available antifungal drugs have therapeutic limitations due to toxicity, narrow spectrum of activity, and intrinsic or acquired drug resistance. Thus, there is an urgent need for new broad-spectrum antifungal agents with low toxicity and a novel mechanism of action. In this context, we have successfully identified several highly promising lead compounds, i.e., aromatic N'-(salicylidene)carbohydrazides, exhibiting excellent antifungal activities against Cryptococcus neoformans, Candida albicans, Aspergillus fumigatus and several other fungi both in vitro and in vivo...
January 24, 2024: Bioorganic & Medicinal Chemistry